Literature DB >> 14739914

Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec).

B Esmaeli, R Diba, M A Ahmadi, H G Saadati, M M Faustina, T R Shepler, M Talpaz, R Fraunfelder, M B Rios, H Kantarjian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14739914     DOI： 10.1038/sj.eye.6701315

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  6 in total

Review 1.  Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review.

Authors:  Shruthi Harish Bindiganavile; Nita Bhat; Andrew G Lee; Dan S Gombos; Nagham Al-Zubidi
Journal:  J Immunother Precis Oncol       Date:  2021-02-25

2.  Differential and opposing effects of imatinib on LPS- and ventilator-induced lung injury.

Authors:  E Letsiou; A N Rizzo; S Sammani; P Naureckas; J R Jacobson; J G N Garcia; S M Dudek
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-12-05       Impact factor: 5.464

3.  Periorbital edema secondary to imatinib mesylate.

Authors:  Collin M McClelland; George J Harocopos; Philip L Custer
Journal:  Clin Ophthalmol       Date:  2010-05-14

4.  Conjunctival hemorrhagic events associated with imatinib mesylate.

Authors:  Franca Radaelli; Claudia Vener; Francesco Ripamonti; Alessandra Iurlo; Mariangela Colombi; Andrea Artoni; Gianluigi Reda; Giorgio Lambertenghi Deliliers
Journal:  Int J Hematol       Date:  2007-12       Impact factor: 2.490

Review 5.  Ocular Toxicity of Targeted Anticancer Agents.

Authors:  Blake H Fortes; Prashant D Tailor; Lauren A Dalvin
Journal:  Drugs       Date:  2021-03-31       Impact factor: 9.546

Review 6.  European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Authors:  J L Steegmann; M Baccarani; M Breccia; L F Casado; V García-Gutiérrez; A Hochhaus; D-W Kim; T D Kim; H J Khoury; P Le Coutre; J Mayer; D Milojkovic; K Porkka; D Rea; G Rosti; S Saussele; R Hehlmann; R E Clark
Journal:  Leukemia       Date:  2016-04-28       Impact factor: 11.528
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.